<DOC>
	<DOC>NCT02762643</DOC>
	<brief_summary>A randomized, open-label, crossover, Phase I clinical trial to compare the pharmacokinetics of DP-R213 (Raloxifenel and Cholecaliferol fixed dose combinations) in comparison to each component administered alone in healthy male volunteers.</brief_summary>
	<brief_title>DP-R213 Pharmacokinetics Study</brief_title>
	<detailed_description />
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>IBW Â±20% signed the informed consent form prior to the study participation Clinically significant disease Previously donate whole blood within 2 months or component blood within 1 month Clinically significant allergic disease Taken IP in other trial within 3 months An impossible one who participates in clinical trial by investigator's decision including laboratory test result</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>DP-R213</keyword>
</DOC>